舍曲林联合氨磺必利治疗难治性强迫症的临床研究

目的:探讨舍曲林联合氨磺必利治疗难治性强迫症的临床疗效及安全性。方法:难治性强迫症患者45例,随机分为对照组23例和实验组22例。对照组单用舍曲林,实验组给予舍曲林合并氨磺必利治疗,均治疗8周。治疗前后采用耶鲁-布朗强迫量表(Y-BOCS)评定强迫症严重程度,不良反应量表(TESS)评定不良反应。结果:治疗8周后,对照组和实验组的总有效率分别为66.7%、90.1%,实验组优于对照组,差异有统计学意义(P0.05)。治疗2周和4周后,实验组Y-BOCS评分较对照组降低(P0.05),治疗8周末实验组的Y-BOCS评分较对照组显著降低(P0.01)。2组组内比较,除对照组在治疗2周末与治疗前比较Y-BOCS评分差异不明显,其余各周评分与治疗前比较均有显著性差异(P0.01)。2组的不良反应中,唾液增多差异有统计学意义(P0.05)。结论:舍曲林联合氨磺必利治疗难治性强迫症与舍曲林单药治疗比较,起效更早、疗效更好,安全性较好。

Effects of Sertraline Combined with Amisulpride Treatment on Refractory Obsessive Compul-sive Disorder

Objective: To explore the efficacy and safety of sertraline combined with amisulpride treatment on re-fractory obsessive-compulsive disorder (OCD). Methods: Forty-five OCD patientswere randomly divided into groups control (n=23) and experimental (n=22). The control group was given sertraline alone for 8 weeks, and the experimental group was given sertraline and amisulpride for 8 weeks. Before and after the treatment, Yale Brown Obsessive-Compulsive Scale (Y-BOCS) was used to assess the severity of symptoms and TESS was used to assess the adverse reactions. Results: After 8 weeks of treatment, the total effective rate of the control and experimental groups were 66.7% and 90.1%. At 2 and 4 weeks of treatment, Y-BOCS score of the experimental group was lower than that of the control group (P<0.05). At 8 weeks of treatment, the Y-BOCS score in the experimental group was significantly lower than that in the control group (P<0.01). For intra-group comparison of the both groups, Y-BOCS score at each week of treatment decreased significantly compared with the score before treatment (P<0.01), except for at 2 weeks of treatment in the control group (no significant difference compared with the score before treat-ment). In light of the adverse reactions, increased salivation showed a significant difference between the 2 groups (P<0.05). Conclusion: Sertraline combined with amisulpride treatment on refractory OCD is better than sertraline monotherapy, showing earlier start of therapeutic efficacy, higher effective rate and more safe.